Furthermore, on-chip analysis of BRAF mutations can also enable screening of melanoma cells within hours of sampling and circumvent the need for DNA isolation and sequencing, thereby suggesting its potential utility in clinical settings. The gene discussed is BRAF; the disease is melanoma.